Healthcare
Live Price
Offline$20.05
+0.00% today
Window Change
+1.52%
Window
May 4, 2026 → Jun 23, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 30 bars · May 4, 2026 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
H.U. Group Holdings, Inc. (MRCHF) is a Healthcare stock with a market cap of $175.48B and listed on OTC. The stock last traded around $20.05 and up 1.5% across the available one-year price window (May 4, 2026 → Jun 23, 2026). Baseline metrics include revenue growth of +2.6%, EPS growth of +136.6%, a dividend yield of 4.0%. What stands out right now is revenue +2.6%, EPS +136.6%, free cash flow +1258.1% with operating margin 1.7% and ROIC 1.4%. The dividend matters to the case here, with a current yield around 4.0%. Valuation already assumes a fairly strong business story at P/E 30.9 and price/sales 0.7. Stock Foundry combines MRCHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MRCHF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MRCHF Max Drawdown
-6.07%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MRCHF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$223.0B
-18.3% YoY
FY Net Income
$17.5B
-41.0% YoY
Free Cash Flow
$14.4B
-28.4% YoY
Revenue Growth
+2.6%
EPS Growth
+136.6%
Gross Margin
28.7%
Net Margin
2.2%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 243.0B | 236.9B | 260.9B | 272.9B | 223.0B |
| Gross Profit | 67.2B | 63.2B | 89.9B | 111.8B | 76.2B |
| Operating Income | 2.6B | -4.0B | 23.4B | 50.5B | 25.4B |
| EBITDA | 23.1B | 13.7B | 43.0B | 56.3B | 33.6B |
| Net Income | 2.8B | -7.6B | 15.7B | 29.6B | 17.5B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 40.9B | 39.9B | 44.2B | 46.5B | 43.0B |
| Total Assets | 279.6B | 290.8B | 297.9B | 286.6B | 252.8B |
| Total Liabilities | 142.3B | 148.3B | 147.9B | 146.4B | 137.5B |
| Shareholder Equity | 137.1B | 142.5B | 150.0B | 140.2B | 115.3B |
| Total Debt | 86.7B | 81.9B | 77.2B | 73.0B | 80.5B |
| Net Debt | 45.8B | 42.0B | 33.0B | 26.5B | 37.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
35.6B
-35.6% YoY
Capital Expenditures
21.2B
+39.7% YoY
Free Cash Flow
14.4B
-28.4% YoY
Key ratios
Gross Margin
28.7%
Operating Margin
1.7%
Net Margin
2.2%
ROE
4.1%
Debt / Equity
0.52x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.